Curcumin as "Curecumin": From kitchen to clinic

Biochemical Pharmacology

Volumn 75, Issue 4, 2008, Pages 787-809

  Goel, Ajay ^a   Kunnumakkara, Ajaikumar B ^b   Aggarwal, Bharat B ^b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anticancer; Curcumin; Natural products

Indexed keywords

CELECOXIB; CORTICOSTEROID; CURCUMIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOCETAXEL; GEMCITABINE; GINKGO BILOBA EXTRACT; HERBACEOUS AGENT; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; P21 ACTIVATED KINASE; PHENYLBUTAZONE; PLACEBO; PROTEIN MDM2; PROTEIN P53; QUERCETIN; SALAZOSULFAPYRIDINE; SULINDAC; UBIDECARENONE; UNCLASSIFIED DRUG; ZYFLAMEND;

ALZHEIMER DISEASE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; ARTICLE; ATHEROSCLEROSIS; CANCER INHIBITION; CARDIOVASCULAR DISEASE; CELL ADHESION; CELL CULTURE; CELL INVASION; CELL SURVIVAL; CLINICAL TRIAL; COLON CANCER; CYTOKINE RELEASE; DIABETES MELLITUS; DOWN REGULATION; DRUG BINDING; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EXCRETION; DRUG SAFETY; DRUG UPTAKE; DRUG USE; ENTERITIS; ENZYME INHIBITION; GALLSTONE FORMATION; GENE REPRESSION; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; LUNG DISEASE; NONHUMAN; PANCREAS CANCER; PANCREATITIS; PARKINSON DISEASE; POLYPOSIS; PRIORITY JOURNAL; PSORIASIS; RADIOSENSITIVITY; SKIN ALLERGY; SKIN DEFECT; TUMOR GROWTH; ULCERATIVE COLITIS; UPREGULATION; URTICARIA; UVEITIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CURCUMIN; ENZYME INHIBITORS; HUMANS; LIGANDS; PROTEIN BINDING; SPICES; TRANSCRIPTION FACTORS;

EID: 38749109673     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.08.016     Document Type: Article

References (207)

1. Newman D.J., Cragg G.M., and Snader K.M. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 66 (2003) 1022-1037
2. Butler M.S. The role of natural product chemistry in drug discovery. J Nat Prod 67 (2004) 2141-2153
3. Balunas M.J., and Kinghorn A.D. Drug discovery from medicinal plants. Life Sci 78 (2005) 431-441
4. Gurib-Fakim A. Medicinal plants: traditions of yesterday and drugs of tomorrow. Mol Aspects Med 27 (2006) 1-93
5. Newman D.J., and Cragg G.M. Natural products as sources of new drugs over the last 25 years. J Nat Prod 70 (2007) 461-477
6. Mukherjee P.K., and Wahile A. Integrated approaches towards drug development from Ayurveda and other Indian system of medicines. J Ethnopharmacol 103 (2006) 25-35
7. Kiuchi F., Goto Y., Sugimoto N., Akao N., Kondo K., and Tsuda Y. Nematocidal activity of turmeric: synergistic action of curcuminoids. Chem Pharm Bull (Tokyo) 41 (1993) 1640-1643
8. Ravindran P.N. Turmeric-the golden spice of life. Turmeric: The genus Curcuma (2006), Taylor and Francis Group p. 1-14
9. Aggarwal B.B., Surh Y.J., and Shishodia S. The molecular targets and therapeutic uses of curcumin in health and disease. Adv Exp Med Biol 595 (2007) Springer publication
10. Daybe F.V. Uber Curcumin. den Farbstoff der Curcumawurzzel Ber 3 (1870) 609
11. Lampe V. Milobedzka. J Ver Dtsch Chem Ges 46 (1913) 2235
12. Aggarwal B.B., Kumar A., and Bharti A.C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23 (2003) 363-398
13. Shen L., and Ji H.F. Theoretical study on physicochemical properties of curcumin. Spectrochim Acta A Mol Biomol Spectrosc 67 (2007) 619-623
14. Bernabe-Pineda M., Ramirez-Silva M.T., Romero-Romo M., Gonzalez-Vergara E., and Rojas-Hernandez A. Determination of acidity constants of curcumin in aqueous solution and apparent rate constant of its decomposition. Spectrochim Acta A Mol Biomol Spectrosc 60 (2004) 1091-1097
15. Wang Y.J., Pan M.H., Cheng A.L., Lin L.I., Ho Y.S., Hsieh C.Y., et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 15 (1997) 1867-1876
16. Tonnesen H.H., and Karlsen J. Studies on curcumin and curcuminoids. VI. Kinetics of curcumin degradation in aqueous solution. Z Lebensm Unters Forsch 180 (1985) 402-404
17. Oetari S., Sudibyo M., Commandeur J.N., Samhoedi R., and Vermeulen N.P. Effects of curcumin on cytochrome P450 and glutathione-S-transferase activities in rat liver. Biochem Pharmacol 51 (1996) 39-45
18. Pan M.H., Huang T.M., and Lin J.K. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 27 (1999) 486-494
19. Somparn P., Phisalaphong C., Nakornchai S., Unchern S., and Morales N.P. Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivatives. Biol Pharm Bull 30 (2007) 74-78
20. Pari L., and Murugan P. Tetrahydrocurcumin prevents brain lipid peroxidation in streptozotocin-induced diabetic rats. J Med Food 10 (2007) 323-329
21. Murugan P., and Pari L. Antioxidant effect of tetrahydrocurcumin in streptozotocin-nicotinamide induced diabetic rats. Life Sci 79 (2006) 1720-1728
22. Tomren M.A., Masson M., Loftsson T., and Tonnesen H.H. Studies on curcumin and curcuminoids XXXI. Symmetric and asymmetric curcuminoids: stability, activity and complexation with cyclodextrin. Int J Pharm 338 (2007) 27-34
23. Govindarajan V.S. Turmeric-chemistry, technology, and quality. Crit Rev Food Sci Nutr 12 (1980) 199-301
24. Ammon H.P., and Wahl M.A. Pharmacology of Curcuma longa. Planta Med 57 (1991) 1-7
25. Araujo C.C., and Leon L.L. Biological activities of Curcuma longa L. Mem Inst Oswaldo Cruz 96 (2001) 723-728
26. Aggarwal B.B., Takada Y., and Oommen O.V. From chemoprevention to chemotherapy: common targets and common goals. Expert Opin Investig Drugs 13 (2004) 1327-1338
27. Sreejayan, and Rao M.N. Nitric oxide scavenging by curcuminoids. J Pharm Pharmacol 49 (1997) 105-107
28. Brouet I., and Ohshima H. Curcumin, an anti-tumour promoter and anti-inflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem Biophys Res Commun 206 (1995) 533-540
29. Dikshit M., Rastogi L., Shukla R., and Srimal R.C. Prevention of ischaemia-induced biochemical changes by curcumin & quinidine in the cat heart. Indian J Med Res 101 (1995) 31-35
30. Rao C.V., Rivenson A., Simi B., and Reddy B.S. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 55 (1995) 259-266
31. Limtrakul P., Lipigorngoson S., Namwong O., Apisariyakul A., and Dunn F.W. Inhibitory effect of dietary curcumin on skin carcinogenesis in mice. Cancer Lett 116 (1997) 197-203
32. Kiso Y., Suzuki Y., Watanabe N., Oshima Y., and Hikino H. Antihepatotoxic principles of Curcuma longa rhizomes. Planta Med 49 (1983) 185-187
33. Srivastava R., Dikshit M., Srimal R.C., and Dhawan B.N. Anti-thrombotic effect of curcumin. Thromb Res 40 (1985) 413-417
34. Nirmala C., and Puvanakrishnan R. Protective role of curcumin against isoproterenol induced myocardial infarction in rats. Mol Cell Biochem 159 (1996) 85-93
35. Venkatesan N. Curcumin attenuation of acute adriamycin myocardial toxicity in rats. Br J Pharmacol 124 (1998) 425-427
36. Srinivasan M. Effect of curcumin on blood sugar as seen in a diabetic subject. Indian J Med Sci 26 (1972) 269-270
37. Babu P.S., and Srinivasan K. Influence of dietary curcumin and cholesterol on the progression of experimentally induced diabetes in albino rat. Mol Cell Biochem 152 (1995) 13-21
38. Arun N., and Nalini N. Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats. Plant Foods Hum Nutr 57 (2002) 41-52
39. Deodhar S.D., Sethi R., and Srimal R.C. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res 71 (1980) 632-634
40. Shankar T.N., Shantha N.V., Ramesh H.P., Murthy I.A., and Murthy V.S. Toxicity studies on turmeric (Curcuma longa): acute toxicity studies in rats, guineapigs & monkeys. Indian J Exp Biol 18 (1980) 73-75
41. Qureshi S., Shah A.H., and Ageel A.M. Toxicity studies on Alpinia galanga and Curcuma longa. Planta Med 58 (1992) 124-127
42. Lao C.D., Ruffin M.Tt., Normolle D., Heath D.D., Murray S.I., Bailey J.M., et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6 (2006) 10
43. Aggarwal B.B., Bhatt I.D., Ichikawa H., Ahn K.S., Sethi G., Sandur S.K., et al. Curcumin-boiological and medicinal properties. Turmeric: the genus Curcuma (2006), Taylor and Francis Group p. 297-368
44. Shishodia S., Singh T., and Chaturvedi M.M. Modulation of transcription factors by curcumin. Adv Exp Med Biol 595 (2007) 127-148
45. Pulla Reddy A.C., Sudharshan E., Appu Rao A.G., and Lokesh B.R. Interaction of curcumin with human serum albumin-a spectroscopic study. Lipids 34 (1999) 1025-1029
46. Zsila F., Bikadi Z., and Simonyi M. Unique, pH-dependent biphasic band shape of the visible circular dichroism of curcumin-serum albumin complex. Biochem Biophys Res Commun 301 (2003) 776-782
47. Barik A., Priyadarsini K.I., and Mohan H. Photophysical studies on binding of curcumin to bovine serum albumins. Photochem Photobiol 77 (2003) 597-603
48. Wang F., Yang J., Wu X., and Liu S. Study of the interaction of proteins with curcumin and SDS and its analytical application. Spectrochim Acta A Mol Biomol Spectrosc 61 (2005) 2650-2656
49. Kunwar A., Barik A., Pandey R., and Priyadarsini K.I. Transport of liposomal and albumin loaded curcumin to living cells: an absorption and fluorescence spectroscopic study. Biochim Biophys Acta 1760 (2006) 1513-1520
50. Zsila F., Bikadi Z., and Simonyi M. Induced circular dichroism spectra reveal binding of the antiinflammatory curcumin to human alpha1-acid glycoprotein. Bioorg Med Chem 12 (2004) 3239-3245
51. Yang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280 (2005) 5892-5901
52. 2+. J Biol Chem 276 (2001) 46905-46911
53. 2+ pumps by curcumin. Curcumin putatively stabilizes the interaction between the nucleotide-binding and phosphorylation domains in the absence of ATP. Eur J Biochem 268 (2001) 6318-6327
54. Reddy S., and Aggarwal B.B. Curcumin is a non-competitive and selective inhibitor of phosphorylase kinase. FEBS Lett 341 (1994) 19-22
55. Shim J.S., Kim J.H., Cho H.Y., Yum Y.N., Kim S.H., Park H.J., et al. Irreversible inhibition of CD13/aminopeptidase N by the antiangiogenic agent curcumin. Chem Biol 10 (2003) 695-704
56. Takeuchi T., Ishidoh T., Iijima H., Kuriyama I., Shimazaki N., Koiwai O., et al. Structural relationship of curcumin derivatives binding to the BRCT domain of human DNA polymerase lambda. Genes Cells 11 (2006) 223-235
57. Leu T.H., Su S.L., Chuang Y.C., and Maa M.C. Direct inhibitory effect of curcumin on Src and focal adhesion kinase activity. Biochem Pharmacol 66 (2003) 2323-2331
58. Awasthi S., Pandya U., Singhal S.S., Lin J.T., Thiviyanathan V., Seifert Jr. W.E., et al. Curcumin-glutathione interactions and the role of human glutathione-S-transferase P1-1. Chem Biol Interact 128 (2000) 19-38
59. Wortelboer H.M., Usta M., van der Velde A.E., Boersma M.G., Spenkelink B., van Zanden J.J., et al. Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin. Chem Res Toxicol 16 (2003) 1642-1651
60. Iersel M.L., Ploemen J.P., Struik I., van Amersfoort C., Keyzer A.E., Schefferlie J.G., et al. Inhibition of glutathione-S-transferase activity in human melanoma cells by alpha,beta-unsaturated carbonyl derivatives. Effects of acrolein, cinnamaldehyde, citral, crotonaldehyde, curcumin, ethacrynic acid, and trans-2-hexenal. Chem Biol Interact 102 (1996) 117-132
61. Jung Y., Xu W., Kim H., Ha N., and Neckers L. Curcumin-induced degradation of ErbB2: a role for the E3 ubiquitin ligase CHIP and the Michael reaction acceptor activity of curcumin. Biochim Biophys Acta 1773 (2007) 383-390
62. Baum L., and Ng A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J Alzheimers Dis 6 (2004) 367-377 discussion 443-9
63. Ishihara M., and Sakagami H. Re-evaluation of cytotoxicity and iron chelation activity of three beta-diketones by semiempirical molecular orbital method. In Vivo 19 (2005) 119-123
64. Jankun J., Aleem A.M., Malgorzewicz S., Szkudlarek M., Zavodszky M.I., Dewitt D.L., et al. Synthetic curcuminoids modulate the arachidonic acid metabolism of human platelet 12-lipoxygenase and reduce sprout formation of human endothelial cells. Mol Cancer Ther 5 (2006) 1371-1382
65. Skrzypczak-Jankun E., Zhou K., McCabe N.P., Selman S.H., and Jankun J. Structure of curcumin in complex with lipoxygenase and its significance in cancer. Int J Mol Med 12 (2003) 17-24
66. Gupta K.K., Bharne S.S., Rathinasamy K., Naik N.R., and Panda D. Dietary antioxidant curcumin inhibits microtubule assembly through tubulin binding. FEBS J 273 (2006) 5320-5332
67. Zsila F., Bikadi Z., and Simonyi M. Circular dichroism spectroscopic studies reveal pH dependent binding of curcumin in the minor groove of natural and synthetic nucleic acids. Org Biomol Chem 2 (2004) 2902-2910
68. Romiti N., Tongiani R., Cervelli F., and Chieli E. Effects of curcumin on P-glycoprotein in primary cultures of rat hepatocytes. Life Sci 62 (1998) 2349-2358
69. Anuchapreeda S., Leechanachai P., Smith M.M., Ambudkar S.V., and Limtrakul P.N. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 64 (2002) 573-582
70. Chearwae W., Anuchapreeda S., Nandigama K., Ambudkar S.V., and Limtrakul P. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. Biochem Pharmacol 68 (2004) 2043-2052
71. Fang J., Lu J., and Holmgren A. Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity. J Biol Chem 280 (2005) 25284-25290
72. Martin-Cordero C., Lopez-Lazaro M., Galvez M., and Ayuso M.J. Curcumin as a DNA topoisomerase II poison. J Enzyme Inhib Med Chem 18 (2003) 505-509
73. Mullally J.E., and Fitzpatrick F.A. Pharmacophore model for novel inhibitors of ubiquitin isopeptidases that induce p53-independent cell death. Mol Pharmacol 62 (2002) 351-358
74. Began G., Sudharshan E., and Appu Rao A.G. Inhibition of lipoxygenase 1 by phosphatidylcholine micelles-bound curcumin. Lipids 33 (1998) 1223-1228
75. Lengyel E., Sawada K., and Salgia R. Tyrosine kinase mutations in human cancer. Curr Mol Med 7 (2007) 77-84
76. Tikhomirov O., and Carpenter G. Identification of ErbB-2 kinase domain motifs required for geldanamycin-induced degradation. Cancer Res 63 (2003) 39-43
77. Aoki H., Takada Y., Kondo S., Sawaya R., Aggarwal B.B., and Kondo Y. Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and ERK signaling pathways. Mol Pharmacol 72 1 (2007) 29-39
78. Grosser T. The pharmacology of selective inhibition of COX-2. Thromb Haemost 96 (2006) 393-400
79. Mitra A., Chakrabarti J., Banerji A., Chatterjee A., and Das B.R. Curcumin, a potential inhibitor of MMP-2 in human laryngeal squamous carcinoma cells HEp2. J Environ Pathol Toxicol Oncol 25 (2006) 679-690
80. Cho J.W., Lee K.S., and Kim C.W. Curcumin attenuates the expression of IL-1beta, IL-6, and TNF-alpha as well as cyclin E in TNF-alpha-treated HaCaT cells; NF-kappaB and MAPKs as potential upstream targets. Int J Mol Med 19 (2007) 469-474
81. Aggarwal S., Ichikawa H., Takada Y., Sandur S.K., Shishodia S., and Aggarwal B.B. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol 69 (2006) 195-206
82. Li M., Zhang Z., Hill D.L., Wang H., and Zhang R. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res 67 (2007) 1988-1996
83. Song G., Mao Y.B., Cai Q.F., Yao L.M., Ouyang G.L., and Bao S.D. Curcumin induces human HT-29 colon adenocarcinoma cell apoptosis by activating p53 and regulating apoptosis-related protein expression. Braz J Med Biol Res 38 (2005) 1791-1798
84. Liontas A., and Yeger H. Curcumin and resveratrol induce apoptosis and nuclear translocation and activation of p53 in human neuroblastoma. Anticancer Res 24 (2004) 987-998
85. Gaedeke J., Noble N.A., and Border W.A. Curcumin blocks fibrosis in anti-Thy 1 glomerulonephritis through up-regulation of heme oxygenase 1. Kidney Int 68 (2005) 2042-2049
86. McNally S.J., Harrison E.M., Ross J.A., Garden O.J., and Wigmore S.J. Curcumin induces heme oxygenase 1 through generation of reactive oxygen species, p38 activation and phosphatase inhibition. Int J Mol Med 19 (2007) 165-172
87. Rao C.V., Simi B., and Reddy B.S. Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon. Carcinogenesis 14 (1993) 2219-2225
88. Huang M.T., Lou Y.R., Ma W., Newmark H.L., Reuhl K.R., and Conney A.H. Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res 54 (1994) 5841-5847
89. Kim J.M., Araki S., Kim D.J., Park C.B., Takasuka N., Baba-Toriyama H., et al. Chemopreventive effects of carotenoids and curcumins on mouse colon carcinogenesis after 1,2-dimethylhydrazine initiation. Carcinogenesis 19 (1998) 81-85
90. Rao C.V., Rivenson A., Simi B., and Reddy B.S. Chemoprevention of colon cancer by dietary curcumin. Ann N Y Acad Sci 768 (1995) 201-204
91. Kawamori T., Lubet R., Steele V.E., Kelloff G.J., Kaskey R.B., Rao C.V., et al. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res 59 (1999) 597-601
92. Collett G.P., Robson C.N., Mathers J.C., and Campbell F.C. Curcumin modifies Apc(min) apoptosis resistance and inhibits 2-amino 1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) induced tumour formation in Apc(min) mice. Carcinogenesis 22 (2001) 821-825
93. Pereira M.A., Grubbs C.J., Barnes L.H., Li H., Olson G.R., Eto I., et al. Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz[a]anthracene-induced mammary cancer in rats. Carcinogenesis 17 (1996) 1305-1311
94. Kwon Y., Malik M., and Magnuson B.A. Inhibition of colonic aberrant crypt foci by curcumin in rats is affected by age. Nutr Cancer 48 (2004) 37-43
95. Shpitz B., Giladi N., Sagiv E., Lev-Ari S., Liberman E., Kazanov D., et al. Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model. Digestion 74 (2006) 140-144
96. Sugimoto K., Hanai H., Tozawa K., Aoshi T., Uchijima M., Nagata T., et al. Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 123 (2002) 1912-1922
97. Salh B., Assi K., Templeman V., Parhar K., Owen D., Gomez-Munoz A., et al. Curcumin attenuates DNB-induced murine colitis. Am J Physiol Gastrointest Liver Physiol 285 (2003) G235-G243
98. Ukil A., Maity S., Karmakar S., Datta N., Vedasiromoni J.R., and Das P.K. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol 139 (2003) 209-218
99. Venkataranganna M.V., Rafiq M., Gopumadhavan S., Peer G., Babu U.V., and Mitra S.K. NCB-02 (standardized Curcumin preparation) protects dinitrochlorobenzene-induced colitis through down-regulation of NFkappa-B and iNOS. World J Gastroenterol 13 (2007) 1103-1107
100. Ushida J., Sugie S., Kawabata K., Pham Q.V., Tanaka T., Fujii K., et al. Chemopreventive effect of curcumin on N-nitrosomethylbenzylamine-induced esophageal carcinogenesis in rats. Jpn J Cancer Res 91 (2000) 893-898
101. Huang M.T., Deschner E.E., Newmark H.L., Wang Z.Y., Ferraro T.A., and Conney A.H. Effect of dietary curcumin and ascorbyl palmitate on azoxymethanol-induced colonic epithelial cell proliferation and focal areas of dysplasia. Cancer Lett 64 (1992) 117-121
102. Perkins S., Verschoyle R.D., Hill K., Parveen I., Threadgill M.D., Sharma R.A., et al. Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 11 (2002) 535-540
103. Azuine M.A., and Bhide S.V. Chemopreventive effect of turmeric against stomach and skin tumors induced by chemical carcinogens in Swiss mice. Nutr Cancer 17 (1992) 77-83
104. Singh S.V., Hu X., Srivastava S.K., Singh M., Xia H., Orchard J.L., et al. Mechanism of inhibition of benzo[a]pyrene-induced forestomach cancer in mice by dietary curcumin. Carcinogenesis 19 (1998) 1357-1360
105. Nagabhushan M., and Bhide S.V. Curcumin as an inhibitor of cancer. J Am Coll Nutr 11 (1992) 192-198
106. Ikezaki S., Nishikawa A., Furukawa F., Kudo K., Nakamura H., Tamura K., et al. Chemopreventive effects of curcumin on glandular stomach carcinogenesis induced by N-methyl-N′-nitro-N-nitrosoguanidine and sodium chloride in rats. Anticancer Res 21 (2001) 3407-3411
107. Chuang S.E., Cheng A.L., Lin J.K., and Kuo M.L. Inhibition by curcumin of diethylnitrosamine-induced hepatic hyperplasia, inflammation, cellular gene products and cell-cycle-related proteins in rats. Food Chem Toxicol 38 (2000) 991-995
108. Hecht S.S., Kenney P.M., Wang M., Trushin N., Agarwal S., Rao A.V., et al. Evaluation of butylated hydroxyanisole, myo-inositol, curcumin, esculetin, resveratrol and lycopene as inhibitors of benzo[a]pyrene plus 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in A/J mice. Cancer Lett 137 (1999) 123-130
109. Huang M.T., Lou Y.R., Xie J.G., Ma W., Lu Y.P., Yen P., et al. Effect of dietary curcumin and dibenzoylmethane on formation of 7,12-dimethylbenz[a]anthracene-induced mammary tumors and lymphomas/leukemias in Sencar mice. Carcinogenesis 19 (1998) 1697-1700
110. Singletary K., MacDonald C., Wallig M., and Fisher C. Inhibition of 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumorigenesis and DMBA-DNA adduct formation by curcumin. Cancer Lett 103 (1996) 137-141
111. Deshpande S.S., Ingle A.D., and Maru G.B. Chemopreventive efficacy of curcumin-free aqueous turmeric extract in 7,12-dimethylbenz[a]anthracene-induced rat mammary tumorigenesis. Cancer Lett 123 (1998) 35-40
112. Inano H., Onoda M., Inafuku N., Kubota M., Kamada Y., Osawa T., et al. Chemoprevention by curcumin during the promotion stage of tumorigenesis of mammary gland in rats irradiated with gamma-rays. Carcinogenesis 20 (1999) 1011-1018
113. Inano H., and Onoda M. Radioprotective action of curcumin extracted from Curcuma longa LINN: inhibitory effect on formation of urinary 8-hydroxy-2′-deoxyguanosine, tumorigenesis, but not mortality, induced by gamma-ray irradiation. Int J Radiat Oncol Biol Phys 53 (2002) 735-743
114. Lin C.C., Ho C.T., and Huang M.T. Mechanistic studies on the inhibitory action of dietary dibenzoylmethane, a beta-diketone analogue of curcumin, on 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis. Proc Natl Sci Counc Repub China B 25 (2001) 158-165
115. Lin C.C., Lu Y.P., Lou Y.R., Ho C.T., Newmark H.H., MacDonald C., et al. Inhibition by dietary dibenzoylmethane of mammary gland proliferation, formation of DMBA-DNA adducts in mammary glands, and mammary tumorigenesis in Sencar mice. Cancer Lett 168 (2001) 125-132
116. Azuine M.A., and Bhide S.V. Protective single/combined treatment with betel leaf and turmeric against methyl (acetoxymethyl) nitrosamine-induced hamster oral carcinogenesis. Int J Cancer 51 (1992) 412-415
117. Tanaka T., Makita H., Ohnishi M., Hirose Y., Wang A., Mori H., et al. Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis by dietary curcumin and hesperidin: comparison with the protective effect of beta-carotene. Cancer Res 54 (1994) 4653-4659
118. Imaida K., Tamano S., Kato K., Ikeda Y., Asamoto M., Takahashi S., et al. Lack of chemopreventive effects of lycopene and curcumin on experimental rat prostate carcinogenesis. Carcinogenesis 22 (2001) 467-472
119. Ishizaki C., Oguro T., Yoshida T., Wen C.Q., Sueki H., and Iijima M. Enhancing effect of ultraviolet A on ornithine decarboxylase induction and dermatitis evoked by 12-o-tetradecanoylphorbol-13-acetate and its inhibition by curcumin in mouse skin. Dermatology 193 (1996) 311-317
120. Huang M.T., Smart R.C., Wong C.Q., and Conney A.H. Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 48 (1988) 5941-5946
121. Lu Y.P., Chang R.L., Huang M.T., and Conney A.H. Inhibitory effect of curcumin on 12-O-tetradecanoylphorbol-13-acetate-induced increase in ornithine decarboxylase mRNA in mouse epidermis. Carcinogenesis 14 (1993) 293-297
122. Huang M.T., Ma W., Lu Y.P., Chang R.L., Fisher C., Manchand P.S., et al. Effects of curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion. Carcinogenesis 16 (1995) 2493-2497
123. Huang M.T., Ma W., Yen P., Xie J.G., Han J., Frenkel K., et al. Inhibitory effects of topical application of low doses of curcumin on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion and oxidized DNA bases in mouse epidermis. Carcinogenesis 18 (1997) 83-88
124. Soudamini K.K., and Kuttan R. Inhibition of chemical carcinogenesis by curcumin. J Ethnopharmacol 27 (1989) 227-233
125. Takaba K., Hirose M., Yoshida Y., Kimura J., Ito N., and Shirai T. Effects of n-tritriacontane-16,18-dione, curcumin, chlorphyllin, dihydroguaiaretic acid, tannic acid and phytic acid on the initiation stage in a rat multi-organ carcinogenesis model. Cancer Lett 113 (1997) 39-46
126. Huang M.T., Lysz T., Ferraro T., Abidi T.F., Laskin J.D., and Conney A.H. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res 51 (1991) 813-819
127. Mahmoud N.N., Carothers A.M., Grunberger D., Bilinski R.T., Churchill M.R., Martucci C., et al. Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. Carcinogenesis 21 (2000) 921-927
128. Kwon Y., and Magnuson B.A. Effect of azoxymethane and curcumin on transcriptional levels of cyclooxygenase-1 and -2 during initiation of colon carcinogenesis. Scand J Gastroenterol 42 (2007) 72-80
129. Sreepriya M., and Bali G. Chemopreventive effects of embelin and curcumin against N-nitrosodiethylamine/phenobarbital-induced hepatocarcinogenesis in Wistar rats. Fitoterapia 76 (2005) 549-555
130. Sreepriya M., and Bali G. Effects of administration of Embelin and Curcumin on lipid peroxidation, hepatic glutathione antioxidant defense and hematopoietic system during N-nitrosodiethylamine/phenobarbital-induced hepatocarcinogenesis in Wistar rats. Mol Cell Biochem 284 (2006) 49-55
131. Kalpana C., Rajasekharan K.N., and Menon V.P. Modulatory effects of curcumin and curcumin analog on circulatory lipid profiles during nicotine-induced toxicity in Wistar rats. J Med Food 8 (2005) 246-250
132. Mahady G.B., Pendland S.L., Yun G., and Lu Z.Z. Turmeric (Curcuma longa) and curcumin inhibit the growth of Helicobacter pylori, a group 1 carcinogen. Anticancer Res 22 (2002) 4179-4181
133. Kuttan R., Bhanumathy P., Nirmala K., and George M.C. Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett 29 (1985) 197-202
134. Ruby A.J., Kuttan G., Babu K.D., Rajasekharan K.N., and Kuttan R. Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett 94 (1995) 79-83
135. Aggarwal B.B., Shishodia S., Takada Y., Banerjee S., Newman R.A., Bueso-Ramos C.E., et al. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 11 (2005) 7490-7498
136. Bachmeier B., Nerlich A.G., Iancu C.M., Cilli M., Schleicher E., Vene R., et al. The chemopreventive polyphenol curcumin prevents hematogenous breast cancer metastases in immunodeficient mice. Cell Physiol Biochem 19 (2007) 137-152
137. Li L., Ahmed B., Mehta K., and Kurzrock R. Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther 6 (2007) 1276-1282
138. Cui S.X., Qu X.J., Xie Y.Y., Zhou L., Nakata M., Makuuchi M., et al. Curcumin inhibits telomerase activity in human cancer cell lines. Int J Mol Med 18 (2006) 227-231
139. Ohashi Y., Tsuchiya Y., Koizumi K., Sakurai H., and Saiki I. Prevention of intrahepatic metastasis by curcumin in an orthotopic implantation model. Oncology 65 (2003) 250-258
140. LoTempio M.M., Veena M.S., Steele H.L., Ramamurthy B., Ramalingam T.S., Cohen A.N., et al. Curcumin suppresses growth of head and neck squamous cell carcinoma. Clin Cancer Res 11 (2005) 6994-7002
141. Odot J., Albert P., Carlier A., Tarpin M., Devy J., and Madoulet C. In vitro and in vivo anti-tumoral effect of curcumin against melanoma cells. Int J Cancer 111 (2004) 381-387
142. Lin Y.G., Kunnumakkara A.B., Nair A., Merritt W.M., Han L.Y., Armaiz-Pena G.N., et al. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-{kappa}B pathway. Clin Cancer Res 13 (2007) 3423-3430
143. Li L., Braiteh F.S., and Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 104 (2005) 1322-1331
144. Kunnumakkara A.B., Guha S., Krishnan S., Diagaradjane P., Gelovani J., and Aggarwal B.B. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67 (2007) 3853-3861
145. Dorai T., Cao Y.C., Dorai B., Buttyan R., and Katz A.E. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate 47 (2001) 293-303
146. Hong J.H., Ahn K.S., Bae E., Jeon S.S., and Choi H.Y. The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo. Prostate Cancer Prostatic Dis 9 (2006) 147-152
147. Menon L.G., Kuttan R., and Kuttan G. Inhibition of lung metastasis in mice induced by B16F10 melanoma cells by polyphenolic compounds. Cancer Lett 95 (1995) 221-225
148. Yoysungnoen P., Wirachwong P., Bhattarakosol P., Niimi H., and Patumraj S. Effects of curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cell-implanted nude mice. Clin Hemorheol Microcirc 34 (2006) 109-115
149. Busquets S., Carbo N., Almendro V., Quiles M.T., Lopez-Soriano F.J., and Argiles J.M. Curcumin, a natural product present in turmeric, decreases tumor growth but does not behave as an anticachectic compound in a rat model. Cancer Lett 167 (2001) 33-38
150. Wahlstrom B., and Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh) 43 (1978) 86-92
151. Holder G.M., Plummer J.L., and Ryan A.J. The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. Xenobiotica 8 (1978) 761-768
152. Ravindranath V., and Chandrasekhara N. Absorption and tissue distribution of curcumin in rats. Toxicology 16 (1980) 259-265
153. Ravindranath V., and Chandrasekhara N. Metabolism of curcumin-studies with [3H]curcumin. Toxicology 22 (1981) 337-344
154. Ireson C., Orr S., Jones D.J., Verschoyle R., Lim C.K., Luo J.L., et al. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 61 (2001) 1058-1064
155. Ireson C.R., Jones D.J., Orr S., Coughtrie M.W., Boocock D.J., Williams M.L., et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 11 (2002) 105-111
156. Garcea G., Jones D.J., Singh R., Dennison A.R., Farmer P.B., Sharma R.A., et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 90 (2004) 1011-1015
157. Hoehle S.I., Pfeiffer E., Solyom A.M., and Metzler M. Metabolism of curcuminoids in tissue slices and subcellular fractions from rat liver. J Agric Food Chem 54 (2006) 756-764
158. Ryu E.K., Choe Y.S., Lee K.H., Choi Y., and Kim B.T. Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem 49 (2006) 6111-6119
159. Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S., et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21 (2001) 2895-2900
160. Sharma R.A., McLelland H.R., Hill K.A., Ireson C.R., Euden S.A., Manson M.M., et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 7 (2001) 1894-1900
161. Garcea G., Berry D.P., Jones D.J., Singh R., Dennison A.R., Farmer P.B., et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 14 (2005) 120-125
162. Shoba G., Joy D., Joseph T., Majeed M., Rajendran R., and Srinivas P.S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64 (1998) 353-356
163. Marczylo T.H., Verschoyle R.D., Cooke D.N., Morazzoni P., Steward W.P., and Gescher A.J. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol 60 (2007) 171-177
164. Bisht S., Feldmann G., Soni S., Ravi R., Karikar C., and Maitra A. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnol 5 (2007) 3
165. Sun A., Shoji M., Lu Y.J., Liotta D.C., and Snyder J.P. Synthesis of EF24-tripeptide chloromethyl ketone: a novel curcumin-related anticancer drug delivery system. J Med Chem 49 (2006) 3153-3158
166. Sandur S.K., Pandey M.K., Sung B., Ahn K.S., Murakami A., Sethi G., et al. Curcumin, demethoxycurcumin, bisdemothoxycurcumin, tetrahydrocurcumin, and turmerones differentially regulate anti-inflammatory and antiproliferative responses through a ROS-independent mechanism. Carcinogenesis 28 8 (2007) 1765-1773
167. Pfeiffer E., Hoehle S.I., Walch S.G., Riess A., Solyom A.M., and Metzler M. Curcuminoids form reactive glucuronides in vitro. J Agric Food Chem 55 (2007) 538-544
168. Sugiyama Y., Kawakishi S., and Osawa T. Involvement of the beta-diketone moiety in the antioxidative mechanism of tetrahydrocurcumin. Biochem Pharmacol 52 (1996) 519-525
169. Okada K., Wangpoengtrakul C., Tanaka T., Toyokuni S., Uchida K., and Osawa T. Curcumin and especially tetrahydrocurcumin ameliorate oxidative stress-induced renal injury in mice. J Nutr 131 (2001) 2090-2095
170. Naito M., Wu X., Nomura H., Kodama M., Kato Y., and Osawa T. The protective effects of tetrahydrocurcumin on oxidative stress in cholesterol-fed rabbits. J Atheroscler Thromb 9 (2002) 243-250
171. Pari L., and Amali D.R. Protective role of tetrahydrocurcumin (THC) an active principle of turmeric on chloroquine induced hepatotoxicity in rats. J Pharm Pharm Sci 8 (2005) 115-123
172. Murugan P., and Pari L. Effect of tetrahydrocurcumin on plasma antioxidants in streptozotocin-nicotinamide experimental diabetes. J Basic Clin Physiol Pharmacol 17 (2006) 231-244
173. Satoskar R.R., Shah S.J., and Shenoy S.G. Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. Int J Clin Pharmacol Ther Toxicol 24 (1986) 651-654
174. Kuttan R., Sudheeran P.C., and Josph C.D. Turmeric and curcumin as topical agents in cancer therapy. Tumori 73 (1987) 29-31
175. Soni K.B., and Kuttan R. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physiol Pharmacol 36 (1992) 273-275
176. Ramirez Bosca A., Soler A., Carrion-Gutierrez M.A., Pamies Mira D., Pardo Zapata J., Diaz-Alperi J., et al. An hydroalcoholic extract of Curcuma longa lowers the abnormally high values of human-plasma fibrinogen. Mech Ageing Dev 114 (2000) 207-210
177. James J.S. Curcumin: clinical trial finds no antiviral effect. AIDS Treat News (1996) 1-2
178. Rasyid A., and Lelo A. The effect of curcumin and placebo on human gall-bladder function: an ultrasound study. Aliment Pharmacol Ther 13 (1999) 245-249
179. Rasyid A., Rahman A.R., Jaalam K., and Lelo A. Effect of different curcumin dosages on human gall bladder. Asia Pac J Clin Nutr 11 (2002) 314-318
180. Lal B., Kapoor A.K., Asthana O.P., Agrawal P.K., Prasad R., Kumar P., et al. Efficacy of curcumin in the management of chronic anterior uveitis. Phytother Res 13 (1999) 318-322
181. Lal B., Kapoor A.K., Agrawal P.K., Asthana O.P., and Srimal R.C. Role of curcumin in idiopathic inflammatory orbital pseudotumours. Phytother Res 14 (2000) 443-447
182. Heng M.C., Song M.K., Harker J., and Heng M.K. Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. Br J Dermatol 143 (2000) 937-949
183. Sharma R.A., Euden S.A., Platton S.L., Cooke D.N., Shafayat A., Hewitt H.R., et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10 (2004) 6847-6854
184. Bundy R., Walker A.F., Middleton R.W., and Booth J. Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. J Altern Complement Med 10 (2004) 1015-1018
185. Shoskes D., Lapierre C., Cruz-Correa M., Muruve N., Rosario R., Fromkin B., et al. Beneficial effects of the bioflavonoids curcumin and quercetin on early function in cadaveric renal transplantation: a randomized placebo controlled trial. Transplantation 80 (2005) 1556-1559
186. Durgaprasad S., Pai C.G., Vasanthkumar, Alvres J.F., and Namitha S. A pilot study of the antioxidant effect of curcumin in tropical pancreatitis. Indian J Med Res 122 (2005) 315-318
187. Holt P.R., Katz S., and Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 50 (2005) 2191-2193
188. Hanai H., Iida T., Takeuchi K., Watanabe F., Maruyama Y., Andoh A., et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4 (2006) 1502-1506
189. Cruz-Correa M., Shoskes D.A., Sanchez P., Zhao R., Hylind L.M., Wexner S.D., et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 4 (2006) 1035-1038
190. Ng T.P., Chiam P.C., Lee T., Chua H.C., Lim L., and Kua E.H. Curry consumption and cognitive function in the elderly. Am J Epidemiol 164 (2006) 898-906
191. Rafailov S., Cammack S., Stone B.A., and Katz A.E. The role of zyflamend, an herbal anti-inflammatory, as a potential chemopreventive agent against prostate cancer: a case report. Integr Cancer Ther 6 (2007) 74-76
192. Di Mario F., Cavallaro L.G., Nouvenne A., Stefani N., Cavestro G.M., Iori V., et al. A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure?. Helicobacter 12 (2007) 238-243
193. Lao C.D., Demierre M.F., and Sondak V.K. Targeting events in melanoma carcinogenesis for the prevention of melanoma. Expert Rev Anticancer Ther 6 (2006) 1559-1568
194. Kobelt G. Health economic issues in rheumatoid arthritis. Scand J Rheumatol 35 (2006) 415-425
195. Chen Y.C., Tsai S.H., Shen S.C., Lin J.K., and Lee W.R. Alternative activation of extracellular signal-regulated protein kinases in curcumin and arsenite-induced HSP70 gene expression in human colorectal carcinoma cells. Eur J Cell Biol 80 (2001) 213-221
196. Dhillon N., Aggarwal B.B., Li L., Chiao P., Sarkar F., Wolff R.A., et al. Phase II trial of curcumin (diferuloyl methane), an NF-κB inhibitor, in patients with advanced pancreatic cancer. J Clin Oncol 24 (2006) 14151
197. Frank N., Knauft J., Amelung F., Nair J., Wesch H., and Bartsch H. No prevention of liver and kidney tumors in Long-Evans Cinnamon rats by dietary curcumin, but inhibition at other sites and of metastases. Mutat Res 523-524 (2003) 127-135
198. Aggarwal B.B., Banerjee S., Bharadwaj U., Sung B., Shishodia S., and Sethi G. Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem Pharmacol 73 (2007) 1024-1032
199. Moos P.J., Edes K., Mullally J.E., and Fitzpatrick F.A. Curcumin impairs tumor suppressor p53 function in colon cancer cells. Carcinogenesis 25 (2004) 1611-1617
200. Tsvetkov P., Asher G., Reiss V., Shaul Y., Sachs L., and Lotem J. Inhibition of NAD(P)H:quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin. Proc Natl Acad Sci USA 102 (2005) 5535-5540
201. Somasundaram S., Edmund N.A., Moore D.T., Small G.W., Shi Y.Y., and Orlowski R.Z. Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res 62 (2002) 3868-3875
202. Hata M., Sasaki E., Ota M., Fujimoto K., Yajima J., Shichida T., et al. Allergic contact dermatitis from curcumin (turmeric). Contact Dermat 36 (1997) 107-108
203. Swierczynska M.K., and Krecisz B. Occupational skin changes in persons working in contact with food spices. Med Pr 49 (1998) 187-190
204. Keith C.T., Borisy A.A., and Stockwell B.R. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 4 (2005) 71-78
205. Sams-Dodd F. Target-based drug discovery: is something wrong?. Drug Discov Today 10 (2005) 139-147
206. Morphy R., Kay C., and Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov Today 9 (2004) 641-651
207. Mencher S.K., and Wang L.G. Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC Clin Pharmacol 5 (2005) 3